Strategies to improve the clinical performance of chimeric antigen receptor-modified T Cells for cancer

Current Gene Therapy

Volumn 13, Issue 1, 2013, Pages 65-70

  Zhang, Qing ^a   Li, Huizhong ^a   Yang, Jie ^a   Li, Liantao ^a   Zhang, Baofu ^a   Li, Jia ^a   Zheng, Junnian ^a  

^a XUZHOU MEDICAL UNIVERSITY   (China)

Author keywords

Adoptive cell therapy; Cancer gene therapy; Cancer immunotherapy; Chimeric antigen receptor; Clinical trial; T cell

Indexed keywords

B7 ANTIGEN; CD3 ANTIGEN; CD86 ANTIGEN; INTERLEUKIN 2; T LYMPHOCYTE RECEPTOR;

ACUTE LYMPHOBLASTIC LEUKEMIA; CANCER IMMUNOTHERAPY; CELL PROLIFERATION; CHRONIC LYMPHATIC LEUKEMIA; CLINICAL TRIAL (TOPIC); FOLLICULAR LYMPHOMA; HUMAN; IMMUNE RESPONSE; KIDNEY CARCINOMA; LARGE CELL LYMPHOMA; NEOPLASM; NEUROBLASTOMA; NONHODGKIN LYMPHOMA; OVARY CANCER; PROTEIN EXPRESSION; REVIEW; T LYMPHOCYTE;

ANTIGENS, NEOPLASM; CLINICAL TRIALS AS TOPIC; HUMANS; IMMUNOTHERAPY, ADOPTIVE; NEOPLASMS; RECEPTORS, ANTIGEN, T-CELL; RECOMBINANT FUSION PROTEINS; T-LYMPHOCYTES;

EID: 84873205156     PISSN: 15665232     EISSN: 18755631     Source Type: Journal    
DOI: 10.2174/156652313804806570     Document Type: Review

References (43)

1. Eshhar Z. The T-body approach: redirecting T cells with antibody specificity. Handb Exp Pharmacol 2008; (181): 329-42.
2. Ngo MC, Rooney CM, Howard JM, et al. Ex vivo gene transfer for improved adoptive immunotherapy of cancer. Hum Mol Genet 2011; 20 (R1): R93-9.
3. Curran KJ, Pegram HJ, Brentjens RJ. Chimeric antigen receptors for T cell immunotherapy: current understanding and future direction. J Gene Med 2012; 14 (6): 405-15.
4. Sadelain M. T-cell engineering for cancer immunotherapy. Cancer J 2009; 15 (6): 451-5.
5. Lou Y, Basha G, Seipp RP, et al. Combining the antigen processing components TAP and Tapasin elicits enhanced tumorfree survival. Clin Cancer Res 2008; 14 (5): 1494-501.
6. Vago L, Perna SK, Zanussi M, et al. Loss of mismatched HLA in leukemia after stem-cell transplantation. N Engl J Med 2009; 361 (5): 478-88.
7. Weijtens ME, Willemsen RA, Valerio D, et al. Single chain Ig/gamma gene-redirected human T lymphocytes produce cytokines, specifically lyse tumor cells, and recycle lytic capacity. J Immunol 1996; 157 (2): 836-43.
8. Kochenderfer JN, Dudley ME, Feldman SA, et al. B-cell depletion and remissions of malignancy along with cytokine-associated toxicity in a clinical trial of anti-CD19 chimeric-antigen-receptortransduced T cells. Blood 2012; 119 (12): 2709-20.
9. Kershaw MH, Westwood JA, Parker LL, et al. A phase I study on adoptive immunotherapy using gene-modified T cells for ovarian cancer. Clin Cancer Res 2006; 12 (20 Pt 1): 6106-15.
10. Kalos M, Levine BL, Porter DL, et al. T Cells with Chimeric Antigen Receptors Have Potent Antitumor Effects and Can Establish Memory in Patients with Advanced Leukemia. Sci Transl Med 2011; 3 (95): 95ra73-95ra73.
11. Brentjens RJ, Riviere I, Park JH, et al. Safety and persistence of adoptively transferred autologous CD19-targeted T cells in patients with relapsed or chemotherapy refractory B-cell leukemias. Blood 2011; 118 (18): 4817-28.
12. Zou W. Immunosuppressive networks in the tumour environment and their therapeutic relevance. Nat Rev Cancer 2005; 5 (4): 263-74.
13. David L. Porter MD, Bruce L. Levine, Ph.D., Michael Kalos, Ph.D., Adam Bagg, M.D., and Carl H. June, M.D. Chimeric Antigen Receptor-Modified T Cells in Chronic Lymphoid Leukemia. N Engl J Med 2011; 365 (20): 9.
14. Kochenderfer JN, Rosenberg SA. Chimeric antigen receptormodified T cells in CLL. N Engl J Med 2011; 365 (20): 1937-8
15. Morgan RA, Yang JC, Kitano M, et al. Case report of a serious adverse event following the administration of T cells transduced with a chimeric antigen receptor recognizing ERBB2. Mol Ther 2010; 18 (4): 843-51.
16. Till BG, Jensen MC, Wang J, et al. CD20-specific adoptive immunotherapy for lymphoma using a chimeric antigen receptor with both CD28 and 4-1BB domains: pilot clinical trial results. Blood 2012; 119 (17): 3940-50.
17. Lamers CH, Langeveld SC, Groot-van Ruijven CM, et al. Genemodified T cells for adoptive immunotherapy of renal cell cancer maintain transgene-specific immune functions in vivo. Cancer Immunol Immunother 2007; 56 (12): 1875-83.
18. Lamers CH, Sleijfer S, Vulto AG, et al. Treatment of metastatic renal cell carcinoma with autologous T-lymphocytes genetically retargeted against carbonic anhydrase IX: first clinical experience. J Clin Oncol 2006; 24 (13): e20-2.
19. Louis CU, Savoldo B, Dotti G, et al. Antitumor activity and longterm fate of chimeric antigen receptor-positive T cells in patients with neuroblastoma. Blood 2011; 118 (23): 6050-6.
20. Pule MA, Savoldo B, Myers GD, et al. Virus-specific T cells engineered to coexpress tumor-specific receptors: persistence and antitumor activity in individuals with neuroblastoma. Nat Med 2008; 14 (11): 1264-70.
21. Till BG, Jensen MC, Wang J, et al. Adoptive immunotherapy for indolent non-Hodgkin lymphoma and mantle cell lymphoma using genetically modified autologous CD20-specific T cells. Blood 2008; 112 (6): 2261-71.
22. Jensen MC, Popplewell L, Cooper LJ, et al. Antitransgene rejection responses contribute to attenuated persistence of adoptively transferred CD20/CD19-specific chimeric antigen receptor redirected T cells in humans. Biol Blood Marrow Transplant 2010; 16 (9): 1245-56.
23. Park JR, Digiusto DL, Slovak M, et al. Adoptive transfer of chimeric antigen receptor re-directed cytolytic T lymphocyte clones in patients with neuroblastoma. Mol Ther 2007; 15 (4): 825-33.
24. Savoldo B, Ramos CA, Liu E, et al. CD28 costimulation improves expansion and persistence of chimeric antigen receptor-modified T cells in lymphoma patients. J Clin Invest 2011; 121 (5): 1822-6.
25. Gandhi M, Jones K. Optimizing tumor-targeting chimeric antigen receptor T cells in B-cell lymphoma patients. Immunotherapy 2011; 3 (12): 1441-3.
26. Kochenderfer JN, Wilson WH, Janik JE, et al. Eradication of Blineage cells and regression of lymphoma in a patient treated with autologous T cells genetically engineered to recognize CD19. Blood 2010; 116 (20): 4099-102.
27. Brentjens R, Yeh R, Bernal Y, et al. Treatment of chronic lymphocytic leukemia with genetically targeted autologous T cells: case report of an unforeseen adverse event in a phase I clinical trial. Mol Ther 2010; 18 (4): 666-8.
28. Milone MC, Fish JD, Carpenito C, et al. Chimeric receptors containing CD137 signal transduction domains mediate enhanced survival of T cells and increased antileukemic efficacy in vivo. Mol Ther 2009; 17 (8): 1453-64.
29. Burns WR, Zhao Y, Frankel TL, et al. A high molecular weight melanoma-associated antigen-specific chimeric antigen receptor redirects lymphocytes to target human melanomas. Cancer Res 2010; 70 (8): 3027-33.
30. Zhao Y, Wang QJ, Yang S, et al. A Herceptin-Based Chimeric Antigen Receptor with Modified Signaling Domains Leads to Enhanced Survival of Transduced T Lymphocytes and Antitumor Activity. J Immunol 2009; 183 (9): 5563-74.
31. Carpenito C, Milone MC, Hassan R, et al. Control of large, established tumor xenografts with genetically retargeted human T cells containing CD28 and CD137 domains. Proc Natl Acad Sci U S A 2009; 106 (9): 3360-5.
32. Gattinoni L, Klebanoff CA, Palmer DC, et al. Acquisition of full effector function in vitro paradoxically impairs the in vivo antitumor efficacy of adoptively transferred CD8+ T cells. J Clin Invest 2005; 115 (6): 1616-26.
33. Li Y, Liu S, Hernandez J, et al. MART-1-specific melanoma tumor-infiltrating lymphocytes maintaining CD28 expression have improved survival and expansion capability following antigenic restimulation in vitro. J Immunol 2010; 184 (1): 452-65.
34. Lamers CH, Willemsen R, van Elzakker P, et al. Immune responses to transgene and retroviral vector in patients treated with ex vivoengineered T cells. Blood 2011; 117 (1): 72-82.
35. Porter DL, Levine BL, Bunin N, et al. A phase 1 trial of donor lymphocyte infusions expanded and activated ex vivo via CD3/CD28 costimulation. Blood 2006; 107 (4): 1325-31.
36. Moon EK, Carpenito C, Sun J, et al. Expression of a functional CCR2 receptor enhances tumor localization and tumor eradication by retargeted human T cells expressing a mesothelin-specific chimeric antibody receptor. Clin Cancer Res 2011; 17(14): 4719-30.
37. Di Stasi A, De Angelis B, Rooney CM, et al. T lymphocytes coexpressing CCR4 and a chimeric antigen receptor targeting CD30 have improved homing and antitumor activity in a Hodgkin tumor model. Blood 2009; 113(25): 6392-402.
38. Shrimali RK, Yu Z, Theoret MR, et al. Antiangiogenic agents can increase lymphocyte infiltration into tumor and enhance the effectiveness of adoptive immunotherapy of cancer. Cancer Res 2010; 70(15): 6171-80.
39. Lipowska-Bhalla G, Gilham DE, Hawkins RE, et al. Targeted immunotherapy of cancer with CAR T cells: achievements and challenges. Cancer Immunol Immunother 2012; 61(7): 953-62.
40. Kumar P, Woon-Khiong C. Optimization of lentiviral vectors generation for biomedical and clinical research purposes: contemporary trends in technology development and applications. Curr Gene Ther 2011; 11(2): 144-53.
41. Yi Y, Noh MJ, Lee KH. Current advances in retroviral gene therapy. Curr Gene Ther 2011; 11(3): 218-28.
42. Jorritsma A, Schotte R, Coccoris M, et al. Prospects and limitations of T cell receptor gene therapy. Curr Gene Ther 2011; 11(4): 276-87.
43. Kandalaft LE, Powell DJ Jr, Coukos G. A phase I clinical trial of adoptive transfer of folate receptor-alpha redirected autologous T cells for recurrent ovarian cancer. J Transl Med 2012; 10: 157.